chalcone has been researched along with Sepsis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, N; Liu, Q; Ren, C; Wang, L; Wu, Y; Yao, R; Yao, Y | 1 |
| Chen, G; Guo, S; Xu, Y | 1 |
| Chen, G; Fang, Q; Jiang, L; Liang, G; Liu, X; Shan, X; Wang, J; Wang, Y; Wang, Z; Wu, W; Zhang, Y | 1 |
3 other study(ies) available for chalcone and Sepsis
| Article | Year |
|---|---|
[Comparison of effects of Xuebijing injection and its component hydroxysafflor yellow A on coagulation and survival rates of septic rats].
Topics: Animals; Chalcone; Drugs, Chinese Herbal; Male; Quinones; Rats; Rats, Sprague-Dawley; Sepsis; Survival Rate; Tumor Necrosis Factor-alpha | 2021 |
[Screening and identification of potential targets of carthamin against sepsis].
Topics: Chalcone; Drugs, Chinese Herbal; Glucosides; Humans; Medicine, Chinese Traditional; Molecular Docking Simulation; Sepsis | 2021 |
MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis.
Topics: Animals; Cell Line; Chalcone; Dose-Response Relationship, Drug; Drug Delivery Systems; Humans; Inflammation; Inflammation Mediators; Lipopolysaccharides; Lymphocyte Antigen 96; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Protein Structure, Secondary; Protein Structure, Tertiary; Sepsis | 2015 |